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ABSTRACT
Background and Objectives: The incidence of inflammatory heart diseases is not yet as high as those of other cardiovas-
cular diseases; however, inflammatory heart diseases do have relatively high mortality rate. Therefore, update information on 
the economic burden of inflammatory heart diseases are necessary in order to appropriate policy making on these diseases. 
Materials and Methods: This study used a number of resources to obtain data, national health insurance statistics, the Korean 
Health Panel, and the causes of death report by the Korean National Statistical Office. The total costs of inflammatory heart 
diseases were estimated as the sum of direct medical care costs, direct non-medical care and indirect costs. Results: The total 
direct cost of inflammatory heart disease was higher in Korean men than that of Korean women and cost due to inpatient was 
higher than that of outpatients cost. The costs to cover premature death were highest among all of the components used to 
determine the total costs for inflammatory heart disease, representing 66.3% of these costs in Korea. Conclusion: Inflam-
matory heart disease has a relatively high mortality rate, and the costs that are associated with premature deaths consume the 
greatest proportion of the costs associated with this disease. In spite of some limitations of study, this could be a reliable evid-
ence of economic burden of inflammatory heart disease. (Korean Circ J 2011;41:712-717)
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Introduction
Inflammatory heart diseases are caused by heart inflam-
mation or muscle failure that may result from a diverse num-
ber of reasons.
1) Pericarditis, endocarditis, myocarditis, and car-
diomyopathy are classified as inflammatory heart diseases. In-
flammatory heart diseases do not yet make up a large pro-
portion of the total heart diseases. Mortality due to cardio-
vascular disease is mainly a result of having coronary heart 
disease in addition to a cerebrovascular disease. The Korean 
mortality rate of all cardiovascular diseases in 2004 was 169.9 
people per 100,000, and that of inflammatory heart disease 
was 2.0 people per 100,000. However, the mortality rate of 
inflammatory heart disease was 11.4 per 100,000 people in 
the United States of America (USA), 9.7 in France, 5.5 in Chi-
na, and 5.1 in Japan, all of which are higher than that reported 
in Korea. Thus, there is a high probability that the death rate 
in Korea will increase in the future.
2)3) 
The severity of inflammatory heart disease seems high com-
pared to the mortality rate. For example, myocarditis is a po-
tentially life-threatening disease, the acute form of which is 
treatable but can progress to chronic myocarditis or dilated car-
diomyopathy (DCM) in cases of severe inflammation that 
may then result in congestive heart failure. Myocarditis also 
causes sudden death among young adults.
4-6) 
Therefore, the economic burden of inflammatory heart dise-
ase is thought to be quite high, although no exact measures 
have been made. According to the 2004 World health organiz-
ation (WHO) report, Korea’s Disability Adjusted Life Years 
(DALY) on cardiovascular disease was estimated to be 1,277 
(per 100,000 population), while the DALY on inflammatory 
heart disease was estimated to be 28 (per 100,000 population).
2) 
However, Korea does not have estimates on any of the groups 
of cardiovascular disease. As a result, we used various sources 
of data in this study to determine the economic burdens of in-Seul-Ki Ko, et al.   713
flammatory heart disease so that the costs could be express-
ed as in currency value.
Materials and Methods
In this study, we measured the economic costs of inflamma-
tory heart disease using a prevalence rate approach. We did 
not separate the existing inflammatory heart disease patients 
from the newly affected patients of 2008 in our study. We cal-
culated the medical costs paid by Korean society as a result 
of these patients.
We used the precedent study by Jung and Ko
7) as a guide to 
measure socioeconomic costs, based on both direct and indi-
rect costs.
8) The direct costs for medical treatment included 
medical non-medical care costs. Direct medical care costs in-
cluded inpatient and outpatient expenses that are paid by 
the insurer, medical treatment costs that are paid by the pa-
tients, non-covered care costs such as meals, high-end ward 
and special care costs, and prescribed pharmaceutical costs. As 
for the direct non-medical costs, transportation fees needed 
to get to the hospital, admission fees and the cost of having a 
caregiver were all considered. Indirect costs factor in lost pro-
ductivity, which refers to the opportunity costs resulting from 
hospital visits, the costs of admission, and the costs of prema-
ture death. 
We can also account for the costs of over-the-counter drugs 
and out-of-pocket expenses (e.g., child care and home aids). 
However, we excluded the costs of over-the-counter drugs and 
out-of-pocket expenses due to objectivity reasons because not 
much data exists with regard to these are out-of-pocket ex-
penses.
In this study, we defined inflammatory heart disease ac-
cording to the International Classification of Disease 10th 
version (ICD-10) codes I30-I32 (pericarditis), I33 (acute and 
subacute endocarditis), I38 (endocarditis, valve unspecified), 
I40 (acute myocarditis) and I42 (cardiomyopathy).
2)9) The 
classifications followed the global burden of disease study of 
WHO.
2) We used the claim records from the Korean National 
Health Insurance Corporation (NHIC) to collect related data 
on inflammatory heart disease medical usage in order to 
calculate the total cost and the average cost per patient. We 
defined patients with inflammatory heart disease as individ-
uals who were diagnosed by a physician or those for whom the 
hospital had submitted a 2008 claim to the NHIC that had 
stated inflammatory heart disease as the primary disease.
The direct costs include the total expenses of both inpa-
tients and outpatients throughout the year paid to treat the 
specified diseases, which in our study were the diseases de-
fined as the major claim codes I30-33, I38, I40, and I42. Non-
covered service expenses were calculated using the NHIC 
data, which includes the survey data of non-covered care costs 
for every patient in 2008 and is based on the non-covered cost 
rate of the total expense. The cost rate of inpatients was 29.3% 
and that of outpatients was 40.2%.
10-12)As for estimating the 
pharmaceutical costs, the average rate of pharmaceutical 
cost among insurance benefit in cardiovascular diseases (is-
chemic heart disease, cerebrovascular disease, rheumatic he-
art disease, hypertensive disease) was applied.
13) The total cost 
of annual transportation related to the treatment of inflamma-
tory heart diseases was estimated by multiplying the number 
of visits (outpatient, emergency room, and inpatient) by the 
cost of transportation.
The average cost for visiting a hospital was estimated at 
\7,597 per one-way trip for inpatients and \777 per one-
way trip for outpatients, based on the results of the 2008 Ko-
rean Medical Expenditure Survey. The equations used to cal-
culate these values are listed below.
14)
Transportation costs of inpatients=the number of total in-
patient visits×average one-way trip cost×2 (round trip)
Transportation costs of outpatients=the number of total 
outpatient visits×average one-way trip cost×2 (round trip)
We informally calculated the average cost of having a 
caregiver since there were no officially published figures. In 
Korea, the care of inpatients is almost exclusively performed 
by a female family member between the ages of 20 to 60 of age. 
As a result, the total number of days a patient was admitted 
was multiplied by the average daily wage of Korean females be-
tween the ages of 20 and 60 years.
15) Indirect costs were de-
termined by calculating the premature death costs and the 
costs that result from productivity loss due to hospitalization 
or clinic visits. In regard to the productivity loss of inpatients, 
we used the average working hours per month and the aver-
age wage per month based on an informed 2008 survey to 
adjust for age, working conditions and type of employment 
2008. We did not calculate productivity loss for patients who 
were not of working age, which in our study were defined as 
children and teenagers (1-19 years old) and older adults (over 
70 years of age).
15)
In order to calculate the costs associated with productivity 
lost in outpatients, we used the average patient visit time, wh-
ich was calculated by multiplying the average time spent dur-
ing outpatient visits by the number of days the outpatient 
would visit the hospital. The average patient visit time was es-
timated to be 1/3 of days, which was assumed to include time 
spent travelling to the appointment, and was assumed to con-
sume one-third of a patient’s daily working hours.
To estimate the loss of expenditure caused by premature 
death, we determined the number of deaths that were due to 
inflammatory heart disease using the cause of death statis-
tics,
16) and we also converted the future incomes of the dead 
patients to their current values by adjusting for age. As we 
previously mentioned, we also factored in the average number 
of working hours and wages per month.714   The Economic Burden of Inflammatory Heart Disease in Korea
Results 
Table 1 presents the distribution of inflammatory heart dise-
ase in Korea. The incidence rate of inflammatory heart dis-
ease in 2008 was 0.016% in male patients and 0.013% in female 
patients. There were no gender-related differences in the in-
cidence rate of adolescents less than 20 years of age. However, 
the incidence rate of males was observed to be higher than 
that of females when the age group was restricted to the up-
per twenties. The total number of visits that outpatients had 
visited was 73,529, in which men were admitted 42,000 days 
and women 31,529 days. As for inpatients, men were admit-
ted for a total of 3,927 days and women were admitted for a 
total of 3,330 days, thus showing that men were admitted 
more often than women. 
Direct costs
The total direct costs of inflammatory heart disease were 
higher in men than in women. The total direct medical ca-
re costs of male outpatients were \7,005,231,000, and those 
of male inpatients were \19,258,801,000. The total direct 
costs of female outpatients were \3,920,444,000 and those 
of female inpatients were \13,972,257,000. When catego-
rized according to age, infant and adolescent outpatients and 
inpatients had the lowest cost, regardless of sex, while adults 
had the highest cost (Table 2 and 3). 
Direct medical care costs
Total direct medical care costs were calculated to be 
\44,156,731,000 (Table 4). Of this amount, 45.5% was paid 
by the insurer, 10.5% was paid in the form of patient copay-
ments, 19.8% was non-covered care cost and 24.1% was pre-
scribed pharmaceutical costs. In the both cases of outpatients 
and inpatients, the total direct medical care costs of male were 
higher than those of females. But women over the age of 70, 
Table 1. Incidences of inflammatory heart disease in males, fe-
males, and total patients (2008)
Age of  
patients 
(years)
Characteristic (persons) Period incidence (%)
Total Male Female Total Male Female
Total 7,183 3,908 3,275 0.014  0.016  0.013 
00-9  139   72   67 0.003  0.003  0.003 
10-19  169  116   53 0.002  0.003  0.002 
20-29  286  179  107 0.004  0.005  0.003 
30-39  510  338  172 0.006  0.008  0.004 
40-49  908  607  301 0.010  0.014  0.007 
50-59 1,270  773  497 0.021  0.025  0.016 
60-69 1,640  904  736 0.041  0.048  0.035 
70-79 1,553  676  877 0.067  0.073  0.062 
80-89  647  219  428 0.089  0.101  0.084 
90-100   61   24   37 0.071 0.134 0.054
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where the costs of outpatients were \1,390,523,000 and 
those of inpatients were \5,746,835,000, higher than 
those calculated for both male outpatients and inpatients 
(\1,202,080,000 and \4,304,362,000, respectively) (Table 2 
and 3). Among the costs of outpatients, the prescribed phar-
maceutical costs occupied more than half of total medical 
cost (68.6%), but in the case of inpatients, the payment by in-
surer ranked the first among cost components (55.5%).
 
Direct nonmedical costs
The transportation fees used for hospital visits of outpa-
tients were approximately \204,304,000, while those of inpa-
tients were approximately \220,532,000. The outpatient cost 
of having a caregiver was \1,096,446,000, and that of inpa-
tients was \5,826,137,000. The total direct nonmedical 
costs were \7,347,419,000, 14.3% of the total direct costs 
(Table 4).
Indirect costs
The productivity loss due to outpatient hospital visits was 
\923,377,000 for men and \529,021,000 for women, which 
was determined using the average salary per day. In cases of 
hospitalization, the costs for men were \2,717,002,000 and 
those for women were \1,456,775,000. The costs resulting 
from premature death were \72,857,496,000 for men and 
\39,321,051,000 for women, which when combined come 
to a total of \112,178,547,000. As a result, the total indirect 
costs due to both productivity loss and premature death were 
\164,599,010,000 (Table 4).
Discussion
This study made use of NHIC claims records to measure 
the medical usage and the social economic burden that results 
from inflammatory heart disease in Korea. According to the 
results, the 2008 economic burden of inflammatory heart 
disease was approximately 169.4 billion won, including both 
the direct and indirect costs. This result is bigger than the cost 
of bladder cancer, which is 104.5 billion won, based on a 
study by Kim et al.
17) Comparing the present study with the 
one by Kim et al. one difference is that their study also con-
sidered complementary and alternative medicine costs when 
measuring the economic burden. 
In this study, as mentioned in the results, of the \44,156, 
731,000 total direct medical care costs, the amount paid by 
the insurer accounted for the largest percentage, 45.5% 
(\20,106,449,000). The sum of the direct costs and the indi-
rect costs was higher in men than in women. But the group of 
aged 70 and more, the direct medical cost in female group was 
higher than those of male group. Because the incidence of in-
flammatory heart disease is higher in male even the aged gr-
oup, the longer life expectancy of female may attribute the 
higher economic burden of old female group. 
Considering the levels of contribution for each category of 
burden of disease, the costs for premature death were highest 
at 66.3%, followed by the amount paid by the insurer at 11.8%, 
prescribed pharmaceutical costs at 6.3%, the costs of non-
covered services at 5.2%, the costs of having a caregiver at 
4.1%, the costs associated with the loss of productivity at 3.3%, 
copayments that are paid by the patients at 2.7%, and the costs 
of transportation fees at 0.3%. Indirect cost, especially the cost 
due to premature death occupies more than half of total eco-
nomic burden of inflammatory heart disease in this study. 
Therefore it is justifiable to invest drastically to prevent the 
disability and mortality due to inflammatory heart disease. For 
example, future research and investment on treatment to 
minimize the mortality will be needed. 
This study has some limitations. First, the range of inflam-
matory heart diseases could have been defined differently. 
We selected and thereby limited the disease codes to I30-33, 
I38, I40, and I42 according to the ICD-10 according to the 
definition of global burden of disease study of WHO. This 
includes the cardiomyopathy, myocarditis, non-tuberculosis 
pericarditis and endocarditis.
2)9) But the definition of inflam-
matory heart disease could be debated. For example, the hy-
pertrophic cardiomyopathy among cardiomyopathy could be 
genetic disease.
18) Also acute endocarditis could result from 
infectious agent rather than self-inflammation. Therefore 
the trend of cost in endocarditis could differ by the reason. 
But in this study, we followed the classification of WHO to 
increase the comparability of other burden of disease study. 
The estimate of burden of disease could be changed with de-
finition. For example, if atherosclerosis was included accord-
ing to World Heart Federation, then the economic burden of 
inflammatory heart disease would have been even higher.
19) 
Secondly, according to the study by Ariza et al.
20) which fo-
cuses on the economic consequences of diabetes and cardio-
vascular disease in the USA, cardiovascular disease is a ma-
jor complication of diabetes. The cost of diabetes-related 
care accounts for a considerable portion of the health care 
expenditure in the USA. This means there is a possibility that 
inflammatory heart disease from complication and primari-
ly developed diabetes could have been measured together or 
omitted. We need to continue to address this problem in fu-
ture studies.
Despite these limitations, this study calculated the eco-
nomic burden of inflammatory heart disease in Korea using 
the claim records of NHIC which is a national representa-
tive. This could be an evidence of economic burden of inflam-
matory heart disease in Korea and could attribute an evidence 
base policy making for manage inflammatory heart diseases. 
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